Additionally, emerging biomarkers such as EGFR exon 20 insertions, ERBB2 mutations, NRG1 fusions, Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C, and tumor mutational burden are increasingly considered. This evidence concerns the gene KRAS and neoplasm.